Straits Times Index
3,282.88 +13.02 (+0.40%) S&P 500
4,145.19 -6.75 (-0.16%) Dow
32,803.47 +76.67 (+0.23%) Nasdaq
12,657.55 -63.04 (-0.50%) BTC-USD
23,243.41 +59.96 (+0.26%) CMC Crypto 200
533.20 -2.02 (-0.38%)
Vaxart, Inc. (VXRT)
After hours:
- Motley Fool
Could This Unknown Stock Beat Moderna in 2023?
Vaxart (NASDAQ: VXRT) might just be gearing up to steal coronavirus vaccine market share from Moderna (NASDAQ: MRNA) in the next couple of years, making its investors wealthy in the process. The biotech's vaccine tablets could have a few advantages that Moderna's shots don't, including one in particular, that might be a public health holy grail at the moment. For Vaxart's stock to beat Moderna's next year, two things need to happen.
- Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
Vaxart (NASDAQ: VXRT) is working on a coronavirus vaccine candidate. Recently, Vaxart said its omicron-specific candidate and its original candidate both protected against the variant in preclinical tests. Of course, even if Vaxart is successful, the company will make it to market much later than bigger rivals.
- Motley Fool
Better Buy: Novavax vs. Vaxart
Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) are both biotechs which rose to prominence as a result of their efforts to develop and commercialize a coronavirus vaccine. Only Novavax has largely accomplished that goal so far, though its product isn't yet approved for sale in the U.S. But do its recent successes make it a better buy? The argument for buying Novavax is that in the near term it'll be raking in global sales of its coronavirus vaccine, which will continue to get approved for use in more and more jurisdictions.
